Beeline Medicines reports promising mid-stage lupus data

Beeline Medicines' afimetoran, acquired from Bristol Myers Squibb, showed better lupus response rates vs placebo in all dose groups, spurring plans for a pivotal trial.

Raccontata daendpoints.news